Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:41:27.623Z.
Calculation as of: 2026-10-06T21:41:27.623Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$3.06B
EV/Sales Ratio
800.75x
TTM Avg
1123.66x
3Y Avg
904.58x
5Y Avg
368.85x
Market Cap
$2.99B
EV/Sales Ratio
6.62x
TTM Avg
9.31x
3Y Avg
10.36x
5Y Avg
140.89x
Market Cap
$3.12B
EV/Sales Ratio
N/A
TTM Avg
1.20x
3Y Avg
895.62x
5Y Avg
895.62x
Market Cap
$3.19B
EV/Sales Ratio
5.07x
TTM Avg
6.76x
3Y Avg
15.91x
5Y Avg
14.09x
Market Cap
$2.77B
EV/Sales Ratio
4.74x
TTM Avg
7.37x
3Y Avg
10.06x
5Y Avg
14.84x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | 800.75x | 1123.66x | 904.58x | 368.85x |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 6.62x | 9.31x | 10.36x | 140.89x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 1.20x | 895.62x | 895.62x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 5.07x | 6.76x | 15.91x | 14.09x |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 4.74x | 7.37x | 10.06x | 14.84x |
| CareDx, Inc (CDNA)vs › | $3.30B | 6.43x | 3.21x | 2.88x | 3.18x |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 4.62x | 3.13x | 3.31x | 5.18x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
